Breaking News

Agenus, Merck in Antibody Development Pact

April 28, 2014

To develop therapeutic antibodies for cancer treatments

Agenus Inc. has entered into a collaboration and license agreement with Merck for the discovery and development of therapeutic antibodies to immune checkpoints for cancer treatments. Agenus will be responsible for discovery and optimization of fully human antibodies against two undisclosed Merck targets using the 4-Antibody Retrocyte Display platform. Merck will be responsible for clinical development and commercialization.
 
Agenus is eligible to receive approximately $100 million in payments associated with the clinical, regulatory and commercial milestones for two candidates, as well as royalties on worldwide product sales.
 
“We are delighted to be working with Merck, who is a leader in the rapidly developing immuno-oncology space," said Bob Stein, MD, Ph.D., chief scientific officer of Agenus. "We believe our Retrocyte Display technology has significant advantages for creation of high quality antibody development candidates. This collaboration broadens our efforts in immuno-oncology beyond our previously disclosed checkpoint programs with a world-class research and development partner."
 
“This collaboration with Agenus complements our active immuno-oncology discovery programs,” said Dr. Eric Rubin, vice president clinical oncology, Merck Research Laboratories. “We look forward to working to advance these programs with the potential to address the unmet medical needs of people with cancer.”

Related Contract Manufacturing:

  • CROs and Today’s  R&D Landscape

    CROs and Today’s R&D Landscape

    Kristin Brooks, Associate Editor, Contract Pharma||November 9, 2016
    John Lewis of ACRO discusses opportunities, challenges, and the future CRO

  • The Human Parts of Mouse Models

    The Human Parts of Mouse Models

    Julia Schueler, Head of in vivo Operations, Oncotest, a Charles River company ||October 11, 2016
    The PDX model system has come back into focus

  • Choosing Oral Formulations for First-in-man Clinical Trials

    Choosing Oral Formulations for First-in-man Clinical Trials

    Jon Sutch, Senior Manager of Formulation Development, Patheon||October 11, 2016
    Early formulations should be simple, but selecting a simple formulation isn’t as easy as it seems